Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al
Eli Lilly is developing tirzepatide for the treatment of type 2 diabetes mellitus (T2DM), obesity, cardiovascular disorders in T2DM, heart failure, non-alcoholic steatohepatitis, obstructive sleep apnoea and for reducing mortality/morbidity in obesity
Studies report improvements in sexual desire, reduced distress, and increased sexual satisfaction
Doing so could lead to the return of symptoms or health conditions you're managing
To account for imbalance between groups, propensity score matching (PSM) including age, gender and pre-existing cardiovascular disease was performed
AFPs, which often force patients to source medicines overseas, may present access concerns according to a new study